The invention relates to a PKD protein kinase inhibitor for use in preventing or treating obesity in a subject, including preferably also related conditions such as diabetes, wherein the PKD protein kinase inhibitor is administered orally, wherein the PKD protein kinase inhibitor is targeted to act locally in the digestive system, especially in the small intestine. The invention also relates to a pharmaceutical composition comprising a PKD protein kinase inhibitor for use according to the invention.

The Nencki Institute is a co-applicant of the patent with University of Würzburg.

For more information contact Technology Transfer Office.